Overview

A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

Status:
Not yet recruiting
Trial end date:
2023-07-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare if two forms of study medicine, Ritlecitinib, get processed differently in healthy adults. This study is seeking participants who are: - aged 18 or older; - male or female who are healthy as determined by medical assessment ; - Body-mass Index (BMI) of 16 to 32, and a total body weight > 45kg. The study will take up to 2.5 months, including the screening period. There will be 5 periods in total for this study. Participants will have to stay at the study clinic for at least 11 days. Participants will take Riltecitinib either as sprinkled in Soft Food or as Intact Blend-In Capsule. On day 1 of each period, participants will take Riltecitinib and have blood samples taken both before and afterwards. Participants will also answer questions for taste assessment purpose. A follow-up phone call will be made at 28 to 35 days after the last study period.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer